EMD Stock Overview
Engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Emyria Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.032 |
| 52 Week High | AU$0.087 |
| 52 Week Low | AU$0.026 |
| Beta | 0.81 |
| 11 Month Change | 6.67% |
| 3 Month Change | -23.81% |
| 1 Year Change | -58.97% |
| 33 Year Change | -90.30% |
| 5 Year Change | n/a |
| Change since IPO | -77.93% |
Recent News & Updates
Recent updates
Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 02
We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely
May 20Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation
Oct 20We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully
Jun 11Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 25Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares
Nov 17Shareholder Returns
| EMD | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | -1.1% |
| 1Y | -59.0% | 61.9% | 16.1% |
Return vs Industry: EMD underperformed the Australian Pharmaceuticals industry which returned 69.7% over the past year.
Return vs Market: EMD underperformed the Australian Market which returned 17.9% over the past year.
Price Volatility
| EMD volatility | |
|---|---|
| EMD Average Weekly Movement | 15.4% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: EMD's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: EMD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Michael Winlo | emyria.com |
Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson’s disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is under preclinical trial program; and provides psychological trauma care facility under the Pax Centre name.
Emyria Limited Fundamentals Summary
| EMD fundamental statistics | |
|---|---|
| Market cap | AU$13.29m |
| Earnings (TTM) | -AU$11.46m |
| Revenue (TTM) | AU$2.20m |
6.0x
P/S Ratio-1.2x
P/E RatioIs EMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMD income statement (TTM) | |
|---|---|
| Revenue | AU$2.20m |
| Cost of Revenue | AU$2.37m |
| Gross Profit | -AU$167.55k |
| Other Expenses | AU$11.29m |
| Earnings | -AU$11.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | -7.61% |
| Net Profit Margin | -520.07% |
| Debt/Equity Ratio | 33.5% |
How did EMD perform over the long term?
See historical performance and comparison